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ABSTRACT
Background. The efficacy of reoperative cervical neck
dissection (RND) in achieving biochemical complete
remission (BCR) (or postreoperation stimulated thyro-
globulin [sTg] of \0.5 ng/mL) remains unclear in
persistent/recurrent papillary thyroid carcinoma (PTC). We
hypothesized that lower postablation sTg levels would
indicate a higher rate of BCR after RND. Our study
examined the association between postablation sTg and
BCR after one or more RNDs.
Methods. Of 199 patients who underwent RND, 81
patients were eligible. The postablation sTg levels (B2
and [2 ng/mL) were correlated with the postreoperation
sTg levels after RNDs. Patients’ clinicopathological char-
acteristics, operative findings, and subsequent RNDs were
compared between those with BCR after RNDs and those
without.
Results. Those with postablation sTg levels of B2 ng/mL
had significantly higher BCR rate after the first RND (77.8
vs. 5.6 %, p \ 0.001), overall BCR after one or more
RNDs (77.8 vs. 9.3 %, p \ 0.001), and better 5-year
recurrence-free survival after the first RND (80.0 vs.
60.1 %, p = 0.049) than those with postablation sTg levels
of [2 ng/mL. Overall BCR gradually decreased after each
subsequent RND. Postablation sTg significantly correlated
with postreoperation sTg (q = 0.509, p \ 0.001). After
adjusting for the number of metastatic lymph nodes excised
at first RND and presence of extranodal extension, pos-
tablation sTg of B 0.2 ng/mL was the only independent
factor for BCR after one or more RNDs (odds ratio 37.0,
95 % confidence interval 5.68–250.0, p = 0.001).
Conclusions. Only a third of patients who underwent one
or more RNDs for persistent/recurrent PTC had BCR
afterward. Postablation sTg level was an independent fac-
tor for BCR. Completeness of the initial operation is
important for the subsequent success of RND.
Papillary thyroid carcinoma (PTC) is the most common
type of differentiated thyroid carcinoma, and its age-
adjusted incidence has doubled in the last 25 years.1
Despite its relatively good prognosis, with a 10-year can-
cer-specific survival above 90 %, locoregional recurrence
is common.2 Local recurrences are found in 5–20 % of
patients with PTC, of which two-thirds are localized in the
cervical lymph nodes.2 For patients treated with total thy-
roidectomy and radioiodine (RAI) ablation in whom all
normal thyroid tissue has been ablated, disease monitoring
or surveillance for persistent/recurrent disease relies on
measurement of thyroglobulin (Tg) and on high-resolution
neck ultrasound (USG).3 Both basal Tg and postablation
stimulated Tg (sTg) by T4 withdrawal or recombinant
human thyroid-stimulating hormone injection are accurate
predictors for future persistent/recurrent disease.4–7 In the
absence of distant metastases, a single postablation sTg
value of [2 ng/mL indicates a high possibility of residual
disease.3,6 Furthermore, the use of high-resolution USG has
increased the identification of small-volume/nonpalpable
neck lymph node metastases. However, the benefit of
surgically removing these asymptomatic small volumes of
metastatic lymph nodes remains unclear.3 The American
Thyroid Association recommends surgical removal of
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clinically significant metastatic lymph nodes to prevent
future locoregional complications.3,8 Therefore, the long-
term efficacy of reoperative cervical neck dissection
(RND) in terms of local control and biochemical remission
(defined by postreoperation sTg) remains controversial. A
few studies have reported the efficacy of RND by evalu-
ating the postreoperation sTg.8–11 A postreoperation sTg
level of \0.5 ng/mL or biochemical complete remission
(BCR) is an accurate surrogate marker for long-term out-
comes after RND.9 However, the rate of attaining BCR
after first or multiple RNDs varied between studies and
factors for BCR after RND remained undefined.8–11
Because most persistent/recurrent disease probably
represents residual disease, we hypothesized that the pos-
tablation sTg value might predict BCR after one or more
RNDs.6,7,9 Our study aimed to evaluate the efficacy of
RND in achieving BCR and to determine factors for BCR
after one or more RNDs.
PATIENTS AND METHODS
A retrospective review was performed on all patients
who underwent RND for locally persistent/recurrent PTC
from 1996 to 2008. Before RND, all already had complete
removal of the thyroid gland either at our institution or
elsewhere. Some patients also had concomitant neck dis-
section involving the central (level VI) and/or lateral
compartment (levels II–V). A standard dose of 3 GBq RAI
ablation was given to all patients 2–3 months after the
initial operation. A sTg level was then checked 6–9 months
after the ablation (i.e., the postablation sTg level). After
that, patients were placed on a surveillance protocol with
Tg monitoring and USG.12,13 Persistent/recurrent PTC was
suspected on the basis of factors like rising trend of
unstimulated Tg, suspicious sonographic lymph node fea-
tures such as hyperechoic punctuations, cystic appearance,
hypervascularization, and round-shaped node without fatty
hilum and/or positive fine-needle aspiration cytology
findings.4,14 Once persistent/recurrent PTC was diagnosed,
further characterization by computed tomography, fluoro-
deoxyglucose–positron emission tomography/computed
tomography, and/or whole body scan was performed. For
those with imageable locoregional persistent/recurrent
disease, RND was generally preferred over observation or
RAI alone, regardless of the volume of detectable disease.
We generally did not proceed to reoperation unless there
was a positive localization study. Two months after RND, a
further dose of RAI ranging between 3 and 5.5 GBq was
given as an adjuvant treatment, depending on the extent of
disease. A postreoperation sTg level was then taken
6–9 months after RAI therapy. For patients requiring two
or more RNDs, a postreoperation sTg was taken each time.
BCR was defined as postreoperation sTg of \0.5 ng/mL.
When calculating the overall BCR, only the last reoperation
sTg value was taken when the patient had multiple RNDs.
In order to evaluate the efficacy of RND on postreop-
eration sTg, patients with proven or suspected distant
metastases as evident by imaging or with known residual
gross disease after initial operation were excluded. Anti-Tg
antibodies were routinely checked for all patients. Patients
with anti-Tg antibodies or with a missing pair of postab-
lation and postreoperation sTg levels were also excluded.
All data relating to the initial operation and subsequent
RNDs were collected prospectively, and follow-up data
were regularly updated in a computerized database. The
present study protocol was approved by the local institu-
tional review board.
Surgical Resection for Persistent/Recurrent PTC
Patients with persistent/recurrent PTC underwent either
formal central (VI), lateral (levels II–V), or both neck
dissections for lymph node recurrence on the basis of the
findings of the preoperative imaging studies. The central
compartment was not routinely explored at the time of
reoperation unless there was suspected or proven disease in
the area. An en-bloc or compartmental neck dissection was
preferred unless certain compartments had been previously
dissected, or a focused neck dissection or completion
compartmental neck dissection was performed. Before
surgery, the exact location of metastatic lymph nodes was
marked on the neck via USG.
Tg Measurement
All Tg levels were measured in the same laboratory
using the same immunometric assay. The assay used was
the Immulite 2000 (Diagnostic Products Corporation,
Roche, Los Angeles, CA). This was calibrated against
the CRM-457 standard. Normal reference range was
\0.5–55 lg/L, and sensitivity was \0.2 lg/L.
Statistical Analysis
Statistical analysis was performed by v2 or Fisher’s
exact tests to compare categorical variables, and the Mann–
Whitney U-test was used to compare continuous variables
between groups. Variables significant in the univariate
analysis were entered into the multivariate analysis. To
improve clinical utility, before entering into the multivar-
iate analysis, potentially significant continuous variables
were converted into categorical variables using their own
median as the cutoff. Binary logistic regression analysis
with a variable entrance criterion of 0.05 or less was
conducted to identify factors associated with BCR after one
B. H.-H. Lang et al.
or more RND. Recurrence-free survival was calculated by
the Kaplan–Meier method, and survival rates were com-
pared by the log-rank test. The Spearman rank correlation
test was used to correlate postablation sTg with postreop-
eration sTg. All statistical analyses were performed by
SPSS software, version 18.0 (SPSS, Chicago, IL).
RESULTS
There were 243 consecutive RNDs performed on 199
patients over the study period. Sixty-four patients (32.1 %)
were excluded because of distant metastases (n = 33),
gross residual tumor left behind (n = 19), or obvious bulky
residual nodal disease detected at initial scan (n = 12).
Forty patients (20.1 %) with anti-thyroglobulin antibodies
and another 14 patients (7.0 %) with a missing pair of
postablation and postreoperation sTg levels were also
excluded. Therefore, 81 patients (40.7 %) with 106 RNDs
were eligible for analysis. Table 1 shows the patients’
baseline characteristics. All the initial selective neck dis-
sections were performed with therapeutic intent (i.e.,
resection of clinically evident lymph node metastases, or
cN1). None had undergone prophylactic central neck dis-
section. After surgery, all patients received RAI ablation,
and of these, eight patients received one further dose of
RAI because of elevated postablation sTg without image-
able residual disease. The median cumulative dose of
RAI was three (range 3–7.5) GBq, and the final median
postablation sTg level was 12.3 (\0.2–126) ng/mL.
Twenty-seven patients (33.3 %) had postablation sTg val-
ues of B2 ng/mL. The median time interval from initial
surgery to first RND was 33.6 (range 13.1–286.9) months,
and the median follow-up period from initial surgery to
time of analysis was 89.5 (range 28.1–375.7) months. The
most common method of diagnosing persistent/residual
disease was by USG without fine-needle aspiration cytol-
ogy (50.6 %). All patients had proven PTC on histology.
Of the patients requiring RND in the lateral compartment
alone, 34 (59.6 %) of 57 already had initial formal lateral
neck dissection, and of those requiring RND in the central
compartment alone, 1 (12.5 %) of eight had initial formal
central neck dissection.
Figure 1 shows the breakdown of the 81 patients
according to the level of postablation sTg levels of B2
and[2 ng/mL. The group with postablation sTg of B2 ng/mL
had significantly higher BCR rates after the first RND (77.8
vs. 5.6 %, p \ 0.001) and overall BCR after one or more
RNDs (77.8 vs. 9.3 %, p \ 0.001) than the group with
postablation sTg of [2 ng/mL. The recurrence-free sur-
vival from initial operation also tended to be longer than
the group with postablation sTg of [2 ng/mL (41.1 vs.
27.8 months, p = 0.071). The 5-year recurrence-free
TABLE 1 Baseline characteristics of 81 patients with RND
Characteristic Value
Age at initial operation (year) 42.6 (11.8–85.3)
Age at first RND (year) 45.2 (13.1–87.4)
Interval between initial operation to
first RND (month)
33.6 (13.1–286.9)
Gender
Male 26 (32.1 %)
Female 55 (67.9 %)
Type of initial operation
Total thyroidectomy 73 (90.1 %)
Completion total thyroidectomy 4 (4.9 %)
Lobectomy followed by completion total
thyroidectomy
4 (4.9 %)
Type of initial concomitant neck dissection
Central compartment 10 (12.3 %)
Lateral compartment 24 (29.6 %)
Central and lateral compartments 24 (29.6 %)
Tumor stage of primary PTC by TNM stage
I 47 (58.0 %)
II 14 (17.3 %)
III 18 (22.2 %)
IV 2 (2.5 %)
Tumor characteristics
Size (cm) 2.0 (0.7–9.0)
Extrathyroidal extension 29 (35.8 %)
Tumor multifocality 45 (55.6 %)
Capsular invasion 39 (48.1 %)
Lymph node metastases (pN1) 65 (80.2 %)
Postablation stimulated thyroglobulin after
initial operation (ng/mL)
12.3 (\0.2–126)
Method of diagnosing persistent/recurrent PTC before first RND
Ultrasound without FNAC 41 (50.6 %)
Ultrasound guided FNAC 20 (24.7 %)
CT/MRI or FDG-PET/CT 20 (24.7 %)
Type of first RND
Focused or completion dissection 48 (59.3 %)
Formal neck dissection 33 (40.7 %)
Extent of first RND
Central compartment only 8 (9.9 %)
Lateral compartment only 57 (70.4 %)
Central and lateral compartments 16 (19.8 %)
No. of RNDs performed
1 65 (80.2 %)
2 9 (11.1 %)
3 5 (6.2 %)
4 2 (2.5 %)
5 0 (0.0 %)
Data are presented as median (range) or n (%)
RND reoperative cervical neck dissection, PTC papillary thyroid car-
cinoma, TNM tumor, node, metastasis staging system, FNAC fine-
needle aspiration cytology, CT computed tomography, MRI magnetic
resonance imaging, FDG–PET fluorodeoxyglucose–positron emission
tomography
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survival after first RND also was significantly better than
the group with postablation sTg of [2 ng/mL (80.0 vs.
60.1 %, p = 0.049). Figure 2 shows the recurrence-free
survival curves after first RND between postablation B2
and [2 ng/mL.
The overall rate of BCR after first RND was 24 (29.6 %)
of 81; the rate of BCR after second RND was 5 (33.3 %) of
15; the rate of BCR after third RND was 0 (0 %) of seven.
The overall rate of BCR after RNDs was 26 (32.1 %) of 81.
At the time of analysis, these 26 patients did not have
detectable persistent/recurrent PTC.
Table 2 shows a comparison of primary tumor charac-
teristics, postablation sTg, and findings at the first RND
between those who experienced BCR after one or more
RNDs (BCR-positive group) and those who did not achieve
BCR after one or more RNDs (BCR-negative group). The
age at initial operation and the age at first RND in the
BCR-negative group tended to be older than in the
BCR-positive group (p = 0.186 and p = 0.077, respec-
tively). Compared to the BCR-negative group, the
BCR-positive group was significantly more likely to have
postablation sTg of B2 ng/mL (80.8 vs. 10.9 %,
p \ 0.001), a higher number of metastatic lymph nodes
excised at first RND (6 vs. 3, p = 0.039), and absent
extranodal extension (3.8 vs. 52.7 %, p \ 0.001). The
BCR-positive group had significantly lower median pos-
tablation sTg than the BCR-negative group (0.5 vs.
17.0 ng/mL, p \ 0.001). Postablation sTg significantly
correlated with postreoperation sTg (q = 0.509, p\0.001).
Table 3 shows a multivariable analysis for BCR after
RNDs. After adjusting for the number of metastatic lymph
nodes excised at first RND (C4 or \4) and extranodal
extension, postablation sTg of B0.2 ng/mL was the only
independent factor or predictor of BCR after RNDs (odds
ratio 37.0, 95 % confidence interval 5.68–250.0,
p = 0.001). Because age at first RND almost reached
significant in the univariate analysis, it was entered as a
continuous variable in the multivariate analysis. However,
postablation sTg of B0.2 ng/mL remained the only inde-
pendent factor or predictor of BCR after RNDs (odds ratio
37.0, 95 % confidence interval 5.21–250.0, p \ 0.001).
DISCUSSION
Although RND is an effective and safe treatment option
for persistent/recurrent PTC, the efficacy of RND in
achieving long-term recurrence-free survival remains
uncertain.8,15 On the basis of the current recommendation,
the primary aim of RND in persistent/recurrent PTC is to
prevent future locoregional complications because only
30–50 % of patients would remain free of disease in the
short term after RND.3,6 Similar to other studies, our study
1st RND
> 2 ng/mL
(n=54)
≤ 2ng/mL
(n=27)
BCR
(n=21) 
No BCR
(n=6) 
Recurrence
(n=3) 
No Recurrence
(n=18) 
2nd RND
BCR
(n=3) 
No BCR
(n=51) 
No Recurrence
(n=3) 
Recurrence
(n=12) 
No Recurrence
(n=39) 
BCR
(n=3) 
No BCR
(n=10)*
BCR
(n=2) 
No Recurrence
(n=6) Post ablation sTg
level
(n=81)
No BCR
(n=39) 
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(n=3) 
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(n=6) 
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FIG. 1 Flowchart of the 81 patients
who required one or more reoperative
cervical neck dissections according to
postablation stimulated thyroglobulin
values of B2 and [2 ng/mL. * 7 out of
10 patients required C3 reoperations.
Abbreviations: BCR biochemical
complete remission, sTg stimulated
thyroglobulin, RND reoperative
cervical neck dissection
FIG. 2 Recurrence-free survival curves after first reoperative cervi-
cal neck dissection between postablation stimulated thyroglobulin
values of B2 and [ 2 ng/mL
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used BCR as a surrogate marker for long-term outcomes
after RND.8–11 Our overall rate of BCR after one or more
RND was 32.1 %, which appeared to be within the range of
21–51 % reported in other studies. However, unlike other
studies, our study showed that after adjusting for the
number of metastatic lymph nodes at first RND and pres-
ence of extranodal extension, postablation sTg level after
initial operation was an independent factor for BCR after
one or more RNDs. Because postablation sTg of [2 ng/mL
usually indicates residual disease after initial treatment,
2 ng/mL was chosen as the cutoff. We found that those
with postablation sTg of B2 ng/mL had a BCR rate of
77.8 %, whereas those with postablation sTg of [2 ng/mL
had a BCR rate of only 5.6 % after first RND. This agreed
with the findings of a recent study that found that a lower
prereoperation sTg level was significantly associated with a
higher BCR rate.9
Although our study did not examine the association
between postablation sTg and prereoperation sTg or
between prereoperation sTg and BCR rate, we would
expect there would be a significant association between
postablation and prereoperation sTg because the majority
of persistent/recurrent disease probably represents sub-
clinical residual disease from initial treatment.6,7,16 This
might also explain the significant association between
postablation sTg and postreoperation sTg. The group with
postablation sTg of B2 ng/mL probably started with a
significantly lower volume of residual disease than the
group with sTg [2 ng/mL, and when the former group
developed detectable recurrence and required RND, the
volume of disease remained relatively small and so could
be more completely excised by surgery. In contrast, by the
time the group with postablation sTg of [2 ng/mL required
RND, the extent of persistent/recurrent PTC might have
progressed beyond local repeat resection. This might
explain why the group with sTg of [2 ng/mL had a sig-
nificantly lower BCR rate and a significantly better 5-year
recurrence-free survival after first RND in the group with
postablation sTg of B2 ng/mL than the group with sTg
of [2 ng/mL (p = 0.049).
Similar to a previous study, we noticed the rate of
achieving BCR gradually decreased with each subsequent
RND.11 None of the seven patients who had three or more
RNDs experienced BCR, although they remained free of
disease at the time of analysis. Our data indicated that the
efficacy of the second reintervention seemed to depend on
the level of postablation sTg. If the postablation sTg
was B2 ng/mL, the efficacy of the second RND for BCR
remained 100 % successful (i.e., 3 of 3), whereas if the
postablation sTg was [2 ng/mL, the efficacy of the second
RND was only 2 (16.7 %) of 12. There are several expla-
nations for this. First, locoregional persistent/recurrent
disease may progress over time, and it may become
TABLE 2 Comparison of characteristics after initial operation and find-
ings at first reoperation
Characteristic BCR-positive
group
BCR-negative
group
p
(n = 26) (n = 55)
Age at initial operation
(year)
30.4 (18.3–59.9) 43.1 (11.8–85.3) 0.186
Age at first RND (year) 34.6 (19.9–60.2) 49.2 (13.1–86.5) 0.077
Gender (M:F) 7:19 19:36 0.604
Primary tumor stage by
TNM stage
0.781
I 16 (61.5) 31 (56.4)
II 5 (19.2) 9 (16.4)
III 5 (19.2) 13 (23.6)
IV 0 (0.0) 2 (3.6)
Primary tumor
characteristics
Tumor size (cm) 2.3 (0.8–5.0) 2.0 (0.7–9.0) 0.442
Extrathyroidal extension 12 (46.2) 27 (49.1) 0.767
Tumor multifocality 14 (53.8) 31 (56.4) 0.923
Capsular invasion 9 (35.6) 30 (54.5) 0.148
LN metastasis (pN1) 19 (73.1) 46 (83.6) 0.345
Tg level \0.001*,b
After ablation
(ng/mL)
0.5 (\0.2–9.7) 7 (1.6–126.0)
B2 ng/mL 21 (80.8) 6 (10.9)
[2 ng/mL 5 (19.2) 49 (89.1)
Type of first RND 0.114
Focused/completion 12 (46.2) 36 (65.5)
Formal dissection 14 (53.8) 19 (34.5)
Extent of first RND 0.144
Central compartment
only
4 (15.4) 4 (7.3)
Lateral compartment
only
20 (76.9) 37 (67.3)
Central and lateral
compartments
2 (7.7) 14 (25.5)
No. of LNs excised
at first RND
13 (3–42) 11 (5–50) 0.767
No. of positive LNs
excised at first RND
6 (1–12) 3 (1–17) 0.039*,b
LN ratio (%)a 43.3 (33.3–53.3) 32.5 (13.3–60.0) 0.326
Presence of extranodal
extension
1 (3.8) 29 (52.7) \0.001*,c
Postreoperation sTg level
after first RND (ng/mL)
0.2 (\0.2–3.0) 17 (0.9–134.1) \0.001*,b
Data are presented as median (range) or n (%). Name of test has been added
for each significant variable
BCR-positive biochemical complete remission, BCR-negative no biochem-
ical complete remission, RND reoperative cervical neck dissection, LN
lymph node, sTg stimulated thyroglobulin level
a LN ratio = (Number of positive lymph nodes excised/number of lymph
nodes excised) 9 100
b Mann-Whitney U test
c Fisher’s Exact test
* Statistically significant at p \ 0.05
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impossible to be completely removed by local resection.
Second, after each reoperation, more scarring is generated
in the operating field, which makes each subsequent RND
more limited and difficult. Although surgical complications
were not specifically evaluated, we think that the decision
for multiple RNDs should be balanced between increasing
surgical risks and decreasing chance of complete resection
or BCR. We were not able to identify any additional pre-
operative clinical factors for BCR. The two clinical factors
associated with BCR—number of positive lymph nodes
excised and extranodal extension—were postoperative
factors only.
Despite these findings, our study had several short-
comings. First, the number of patients was relatively small,
which limited the power of the study. Also, because of the
exclusion criteria, over half of the consecutive patients had
to be excluded, so our cohort represented a highly selected
patient group. Because none of the patients underwent
concomitant prophylactic central neck dissection at the
initial operation, it remains unknown whether this dissec-
tion might have affected the BCR rate after RND.
Preoperative USG is known to have a low sensitivity in
detecting central compartment metastases.12,17 Also,
because we did not routinely explore the central compart-
ment at the time of RND unless there was suspected
disease, it was unknown whether there was still subclinical
residual disease in the central compartment and whether
clearing this compartment might further improve the BCR
rate. Because the data for prereoperative sTg levels were
not available, our findings and postulations await confir-
mation by future studies.
In conclusion, only a third of patients who underwent
RND for persistent/recurrent PTC experienced BCR
afterward. Postablation sTg level significantly correlated
with postreoperation sTg level. After adjusting for the
number of metastatic lymph nodes at first RND and the
presence of extranodal extension, postablation sTg level
was an independent factor for BCR after one or more
RNDs. Our findings highlight the importance of the com-
pleteness of the first operation on the subsequent success of
RNDs. Concomitant prophylactic central neck dissection
may play a critical role in achieving better completeness in
the first operation.
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